Study of FIH of STX-241 in Locally Advanced or Metastatic NSCLC Resistant to EGFR TKIs

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

171

Participants

Timeline

Start Date

September 17, 2024

Primary Completion Date

November 20, 2027

Study Completion Date

July 31, 2030

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

STX-241

"Film-coated tablet~Route of administration: Oral"

Trial Locations (16)

1307

RECRUITING

Universitätsklinikum Carl Gustav Carus Dresden, Dresden

8035

RECRUITING

Vall d'Hebron Institut d'Oncologia, Barcelona

10002

RECRUITING

National Taiwan University Hospital, Taipei

11217

RECRUITING

Taipei Veterans General Hospital, Taipei

13385

RECRUITING

CHU Hôpital de la Timone, Marseille

28046

RECRUITING

Hospital Universitario La Paz, Madrid

28050

RECRUITING

Centro Integral Oncológico Clara Campal (CIOCC), Madrid

31059

RECRUITING

Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse

37203

RECRUITING

Sarah Cannon Research Institute (SCRI) (The SCRI Oncology Research Consortium), Nashville

44800

RECRUITING

Institut de Cancérologie de l'Ouest (ICO) - René Gauducheau, Saint-Herblain

69008

RECRUITING

Centre Léon Bérard, Lyon

77030

RECRUITING

Oncology Consultants (OC) - Texas Medical Center - Cancer Center, Houston

94800

RECRUITING

Gustave Roussy, Villejuif

200120

RECRUITING

Shanghai East Hospital, Tongji University, Shanghai

300060

RECRUITING

Tianjin Medical University Cancer Institute and Hospital, Tianjin

1066 CX

RECRUITING

Netherlands Cancer Institute, Amsterdam

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY